Moderna's Recent Surge Amid Cancer Vaccine Trial Success
Moderna (NASDAQ: MRNA) shares have surged by approximately 127% in recent weeks, driven primarily by positive results from its phase 3 INTerpath-001 trial involving a combination of Intismeran Autogene and Merck's Keytruda for treating melanoma. This marks a significant turnaround after post-pandemic skepticism about the company’s future beyond its mRNA vaccine technology. The market has responded positively to Moderna's progress in oncology, suggesting potential long-term value despite current financial challenges such as forecasted losses of $8.55 per share for 2026 and estimated revenue of just $2.1 billion this year against a nearly $60 billion valuation. However, analysts caution that the stock’s rapid rise may be partly due to short squeezes or overhyped expectations given commercialization is still years away. Investors are advised to consider whether further weakness might present better entry points.
